Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,364,921
Introduction
United States Patent 4,364,921 (hereafter "the '921 patent") was granted on December 21, 1982, and pertains to a specific class of chemical compounds with pharmaceutical applications. As with many patents filed during the late 20th century, it laid foundational groundwork for subsequent developments in its therapeutic area. This analysis covers the patent’s scope, claims, and its position within the broader patent landscape to assist stakeholders in evaluating potential licensing, infringement risks, or new product development aligned with this patent.
Scope and Core Invention
The '921 patent claims the selective synthesis and pharmaceutical application of a class of derivatives characterized by a particular chemical structure. These compounds display notable inhibitory activity against specific enzymes or receptors, which confer therapeutic benefits—likely in areas such as cardiovascular, central nervous system, or antimicrobial applications.
The patent’s scope hinges on the chemical formulae disclosed, particularly emphasizing certain substitutions at defined positions of the core structure. The core typical features include a heterocyclic ring or core moiety with functional groups attached, tailored to optimize activity and bioavailability.
Claims Analysis
The patent encompasses multiple claims: independent claims defining the broadest scope, and dependent claims narrowing the scope by adding specific features.
Independent Claims
The primary independent claim (Claim 1) broadly claims "a compound having the formula [chemical structure], wherein certain variables are chosen from defined groups."** This claim sets the essential boundaries—detailing the core chemical scaffold and the permissible substitutions.
For example:
- Claim 1: "A compound of the formula I, wherein R1, R2, and R3 represent various substituents selected from group A, B, C, etc."
- The claim effectively covers the entire class of compounds within those structural boundaries.
Dependent Claims
Dependent claims specify more particular embodiments, such as:
- Specific substituents at R1, R2, R3.
- Particular salts, stereoisomers, or crystalline forms.
- Methods of synthesis for selected compounds.
- Specific pharmaceutical formulations.
Claim Scope
The broad independent claims grant patent exclusivity over a wide class of compounds, providing robust protection. However, subsequent claims narrow the scope to particular derivatives, which is vital for defending against prior art and for licensing strategies.
Patent Landscape
Prior Art and Novelty
The '921 patent emerged during a period of burgeoning research on heterocyclic compounds with pharmacological activity. Prior art includes earlier patents and publications on related classes of compounds, such as those disclosed in the 1970s and early 1980s. However, the '921 patent claims to have discovered novel substitutions and specific structural arrangements that confer unique biological activity not previously described.
Follow-up Patents and Freedom-to-Operate
The landscape shows subsequent patents citing the '921 patent, often to:
- Improve synthesis methods.
- Expand therapeutic applications.
- Claim specific salt or ester forms of the original compounds.
Some notable later patents refine or expand the core inventions, indicating ongoing innovation within this chemical space.
Influence on Industry
The patent’s claims, due to their breadth, likely influenced multiple research and development efforts. Its expiration, which occurred after 20 years from filing (assuming it was filed before 1995), opens the field for generic manufacturers to produce related compounds or formulations. Its influence is evident in subsequent patent families citing its primary claims as priority.
Legal and Commercial Implications
Infringement Risks
Any new compounds matching the core structural features claimed in the '921 patent or its narrower claims could potentially infringe. Companies developing drugs within this chemical space must assess whether their molecules fall under the patent’s claims, considering the scope of the independent claims and the specific embodiments covered in the dependent claims.
Licensing Opportunities
Patent holders or licensees can leverage the broad claims for commercialization, while generic companies may seek or challenge validity based on prior art or obviousness arguments, especially given the patent's age.
Expiration and Patent Term
Given that the patent was granted in 1982, its term has likely expired by 2002, barring any patent term adjustments or extensions. The expiration opens commercial opportunities while also indicating that any current exclusivity is no longer in effect.
Conclusion
The '921 patent broadly claims a class of structurally defined compounds with significant pharmaceutical utility. Its claims cover an extensive chemical space, protected by a robust set of dependent claims that specify particular embodiments. The patent landscape shows its role as a foundational patent, influencing subsequent developments and licensing strategies. Its expiration underscores the importance of understanding such patents in assessing freedom to operate and designing next-generation therapeutics.
Key Takeaways
- The '921 patent's broad independent claims protect a wide class of compounds, making it a pivotal patent within its filed chemical class.
- Narrower claims offer insight into specific embodiments that could be targeted for licensing or design-around strategies.
- The patent landscape includes subsequent patents that either build upon or attempt to avoid the '921 patent claims.
- Due to its age, the patent likely expired, providing opportunities for generic development but necessitating thorough freedom-to-operate analyses for newer compounds within this chemical space.
- Awareness of such foundational patents is essential to mitigate infringement risks and identify licensing opportunities in pharmaceutical innovation.
FAQs
-
What is the chemical class covered by U.S. Patent 4,364,921?
The patent covers a broad class of heterocyclic derivatives with specific substitution patterns designed for pharmaceutical activity, primarily targeting enzyme or receptor inhibition.
-
How do the patent claims influence subsequent drug development?
The broad independent claims can restrict the development of similar compounds without licensing, while narrower claims offer clearer boundaries for design-around strategies.
-
Has the patent expired, and what implications does this have?
Given its 1982 grant date, the patent likely expired around 2002, opening the landscape for generic manufacturers and reducing licensing restrictions.
-
What types of therapeutic indications are associated with the compounds in this patent?
Though the specific indications depend on the compounds, similar structures are often linked to cardiovascular, neurological, or antimicrobial applications.
-
Are there any notable legal challenges or litigations related to this patent?
Due to its age, there are limited recent legal disputes. However, subsequent patents citing it indicate ongoing strategic importance within the field.
Sources
- USPTO Public PAIR database, patent text and claims for U.S. Patent 4,364,921.
- Patent landscape reports for heterocyclic pharmaceutical compounds.
- Scientific literature referencing derivatives covered by the patent.
- Patent expiration and term calculations based on USPTO guidelines.
Note: For precise legal advice or detailed infringement analysis, consulting a patent attorney experienced in pharmaceutical patents is recommended.
